Publication Name	World Journal of Clinical Cases
Manuscript ID	94075
Country	Lebanon

Received	2024-03-10 21:54
Peer-Review Started	2024-03-10 21:54
To Make the First Decision
Return for Revision	2024-06-18 03:47
Revised	2024-07-11 15:53
Second Decision	2024-08-01 02:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-08-01 09:26
Articles in Press	2024-08-01 09:26
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-08-06 00:10
Typeset the Manuscript	2024-08-23 06:42
Publish the Manuscript Online	2024-09-11 06:37

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Refractory ulcerative colitis: Upadacitinib versus other biologics
Manuscript Source	Invited Manuscript
All Author List	Said G Farhat and jessy G Fadel
ORCID	Author(s) ORCID Number Said G Farhat http://orcid.org/0000-0002-8071-4681
Funding Agency and Grant Number
Corresponding Author	Said G Farhat, MD, Associate Professor, Department of Gastroenterology Research, Saint George University of Beirut, Rmeil Street, Ashrafieh, Beirut 00000, Lebanon. saidfarhat@hotmail.com
Key Words	Refractory; Ulcerative colitis; Upadacitinib; Ustekinumab; Vedolizumab
Core Tip	Ulcerative colitis (UC), major type of inflammatory bowel disease whose treatment is sometimes challenging and several patients do not respond well to the available therapies. We report the case of a patient diagnosed with refractory UC, with primary non-response to infliximab and vedolizumab (VDZ). The patient experienced recurrent symptoms after receiving mesalazine, prednisone, azathioprine, infliximab, and VDZ for more than four years. Through maximizing the upadacitinib (UPA) treatment, UC remission was achieved. Our report suggests that the small-molecule UPA may be a new treatment option that requires further research.
Publish Date	2024-09-11 06:37
Citation	<p>Farhat SG, Fadel JG. Refractory ulcerative colitis: Upadacitinib versus other biologics. <i>World J Clin Cases</i> 2024; 12(31): 6425-6427</p>
URL	https://www.wjgnet.com/2307-8960/full/v12/i31/6425.htm
DOI	https://dx.doi.org/10.12998/wjcc.v12.i31.6425

Full Article (PDF)	WJCC-12-6425-with-cover.pdf
Manuscript File	94075_Auto_Edited_011056.docx
Answering Reviewers	94075-answering-reviewers.pdf
Audio Core Tip	94075-audio.mp3
Conflict-of-Interest Disclosure Form	94075-conflict-of-interest-statement.pdf
Copyright License Agreement	94075-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	94075-non-native-speakers.pdf
Peer-review Report	94075-peer-reviews.pdf
Scientific Misconduct Check	94075-scientific-misconduct-check.png
Scientific Editor Work List	94075-scientific-editor-work-list.pdf
CrossCheck Report	94075-crosscheck-report.pdf